Worried you’ll need to cover the costs of your Crohn’s disease or ulcerative colitis medication, or whether it will still be covered if you move to another province? Have you ever wondered why all Crohn’s and colitis treatments are not available across Canada or in all provinces? Guest speaker—Laura Roulston, Senior Consultant, Market Access and Payer Strategies at PDCI Market Access, a division of McKesson Canada—discusses everything related to access to treatments in Canada.
Laura Roulston Sr. Consultant, Market Access and Payer Strategies, PDCI
Laura is a member of PDCI’s Commercialization and Launch Team, where she advises pharmaceutical manufacturers on market access, pricing, and reimbursement strategies within the Canadian healthcare system. She has experience across a range of therapeutic areas, including both conventional and specialized treatments. Laura’s work focuses on addressing access challenges and delivering impactful solutions that help bridge the gaps in patient access to innovative therapies in Canada.